New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1484-1491

  Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

AREA UNDER THE CURVE; ARTICLE; DRUG SENSITIVITY; LUNG ALVEOLUS EPITHELIUM; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; QUINOLINES; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77950129575     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01474-09     Document Type: Article

References (68)

1. Allison, S. T. 1956. Pyrazinamide-isoniazid in low dosage in treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 74:400-409.
2. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
3. Ambrose, P. G., A. K. Meagher, J. A. Passarell, S. A. Van Wart, B. B. Cirincione, S. M. Bhavnani, and E. Ellis-Grosse. 2009. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn. Microbiol. Infect. Dis. 63:155-159.
4. Anonymous. 2009. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance, 2000-2007. World Health Organization, Geneva, Switzerland.
5. Bidstrup, C., P. H. Andersen, P. Skinhoj, and A. B. Andersen. 2002. Tuberculous meningitis in a country with a low incidence of tuberculosis: still a serious disease and a diagnostic challenge. Scand. J. Infect. Dis. 34:811-814.
6. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
7. Bock, N. N., T. R. Sterling, C. D. Hamilton, C. Pachucki, Y. C. Wang, D. S. Conwell, A. Mosher, M. Samuels, and A. Vernon. 2002. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Respir. Crit. Care Med. 165:1526-1530.
8. Booker, B. M., P. F. Smith, A. Forrest, J. Bullock, P. Kelchlin, S. M. Bhavnani, R. N. Jones, and P. G. Ambrose. 2005. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi. Antimicrob. Agents Chemother. 49:1775-1781.
9. British Medical Research Council. 1969. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 50:81-114.
10. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
11. Canetti, G., S. Froman, J. Grosset, P. Hauduroy, M. Langerova, H. T. Mahler, G. Meissner, D. A. Mitchison, and L. Sula. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. W. H. O. 29:565-578.
12. Cattamanchi, A., R. B. Dantes, J. Z. Metcalfe, L. G. Jarlsberg, J. Grinsdale, L. M. Kawamura, D. Osmond, P. C. Hopewell, and P. Nahid. 2009. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin. Infect. Dis. 48:179-185.
13. Chideya, S., C. A. Winston, C. A. Peloquin, W. Z. Bradford, P. C. Hopewell, C. D. Wells, A. L. Reingold, T. A. Kenyon, T. L. Moeti, and J. W. Tappero. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694.
14. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Conde, M. B., A. Efron, C. Loredo, G. R. De Souza, N. P. Graca, M. C. Cezar, M. Ram, M. A. Chaudhary, W. R. Bishai, A. L. Kritski, and R. E. Chaisson. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
16. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1999. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43:1329-1333.
17. Conte, J. E., Jr., J. A. Golden, J. Kipps, E. T. Lin, and E. Zurlinden. 2001. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob. Agents Chemother. 45:2891-2896.
18. Conte, J. E., J. A. Golden, J. E. Kipps, E. T. Lin, and E. Zurlinden. 2004. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin. Pharmacokinet. 43:395-404.
19. Conte, J. E., Jr., J. A. Golden, M. McQuitty, J. Kipps, S. Duncan, E. McKenna, and E. Zurlinden. 2002. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. Antimicrob. Agents Chemother. 46:2358-2364.
20. Cox, H., Y. Kebede, S. Allamuratova, G. Ismailov, Z. Davletmuratova, G. Byrnes, C. Stone, S. Niemann, S. Rusch-Gerdes, L. Blok, and D. Doshetov. 2006. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med. 3:e384.
21. Craig, W. A. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-19. In C. H. Nightangle, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and practice. Informa Healthcare USA, Inc., New York, NY.
22. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
23. Dalhoff, A., P. G. Ambrose, and J. W. Mouton. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305.
24. Dandara, C., C. M. Masimirembwa, A. Magimba, S. Kaaya, J. Sayi, D. K. Sommers, J. R. Snyman, and J. A. Hasler. 2003. Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C3T and 590G3A. Pharmacogenetics 13:55-58.
25. D'Argenio, D. Z., A. Schumitzky, and X. Wang. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
26. Diacon, A. H., R. F. Patientia, A. Venter, P. D. van Helden, P. J. Smith, H. McIlleron, J. S. Maritz, and P. R. Donald. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994-2996.
27. Diacon, A. H., A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C. Pistorius, R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J. C. Palomino, T. De Marez, R. P. van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, K. de Beule, K. Andries, and D. F. Mc Neeley. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405.
28. Donald, P. R., D. Maher, J. S. Maritz, and S. Qazi. 2006. Ethambutol dosage for the treatment of children: literature review and recommendations. Int. J. Tuberc. Lung Dis. 10:1318-1330.
29. Dorman, S. E., J. L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C. M. Heilig, J. Bernardo, S. Choudhri, J. H. Grosset, E. Guy, P. Guyadeen, M. C. Leus, G. Maltas, D. Menzies, E. L. Nuermberger, M. Villarino, A. Vernon, and R. E. Chaisson. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
30. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
31. Goutelle, S., L. Bourguignon, P. H. Maire, G. M. Van, J. E. Conte, Jr., and R. W. Jelliffe. 2009. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob. Agents Chemother. 53:2974-2981.
32. Gumbo, T., A. Louie, M. R. Deziel, W. Liu, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788.
33. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
34. Gumbo, T., A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51: 2329-2336.
35. Gumbo, T., C. S. W. Siyambalapitiyage Dona, C. Meek, and R. Leff. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
36. Heifets, L., and T. Sanchez. 2000. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 38:1498-1501.
37. Heifets, L. B. 1991. Antituberculosis drugs: antimicrobial activity in vitro, p. 13-57. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Boca Raton, FL.
38. Jayaram, R., S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, and V. Balasubramanian. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
39. Jayaram, R., R. K. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
40. Katiyar, S. K., S. Bihari, and S. Prakash. 2008. Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum. J. Postgrad. Med. 54:245-246.
41. Kiem, S., and J. J. Schentag. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob. Agents Chemother. 52:24-36.
42. Kinzig-Schippers, M., D. Tomalik-Scharte, A. Jetter, B. Scheidel, V. Jakob, M. Rodamer, I. Cascorbi, O. Doroshyenko, F. Sorgel, and U. Fuhr. 2005. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49:1733-1738.
43. Lin, H. J., C. Y. Han, B. K. Lin, and S. Hardy. 1994. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125-134.
44. MacGowan, A. P., R. Reynolds, A. R. Noel, and K. E. Bowker. 2009. Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints. Antimicrob. Agents Chemother. 53:5181-5184.
45. McDowell, M. A., C. D. Fryar, R. Hirsch, and C. L. Ogden. 2005. Anthropometric reference data for children and adults: U.S. population, 1999-2002. Number 361. National Center for Health Statistics, Hyattsville, MD.
46. Menzies, D., A. Benedetti, A. Paydar, I. Martin, S. Royce, M. Pai, A. Vernon, C. Lienhardt, and W. Burman. 2009. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and metaanalysis. PLoS Med. 6:e1000146.
47. Mitchison, D. A., and A. J. Nunn. 1986. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis. 133:423-430.
48. Moulding, T. S. 1981. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am. Rev. Respir. Dis. 123:262-264.
49. Mouton, J. W., M. L. van Ogtrop, D. Andes, and W. A. Craig. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob. Agents Chemother. 43:2473-2478.
50. Ogden, C. L., M. D. Carroll, L. R. Curtin, M. A. McDowell, C. J. Tabak, and K. M. Flegal. 2006. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555.
51. Pasipanodya, J. G., T. L. Miller, M. Vecino, G. Munguia, R. Garmon, S. Bae, G. Drewyer, and S. E. Weis. 2007. Pulmonary impairment after tuberculosis. Chest 131:1817-1824.
52. Peloquin, C. A., D. J. Hadad, L. P. Molino, M. Palaci, W. H. Boom, R. Dietze, and J. L. Johnson. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857.
53. Peloquin, C. A., G. S. Jaresko, C. L. Yong, A. C. Keung, A. E. Bulpitt, and R. W. Jelliffe. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670-2679.
54. Rodriguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
55. Salfinger, M., and L. B. Heifets. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob. Agents Chemother. 32:1002-1004.
56. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
57. Shaw, J. E., J. G. Pasipanodya, and T. Gumbo. Meningeal tuberculosis has very poor long term mortality despite standard therapy. Medicine (Baltimore), in press.
58. Sheiner, L. B., B. Rosenberg, and V. V. Marathe. 1977. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 5:445-479.
59. Sheiner, L. B., B. Rosenberg, and K. L. Melmon. 1972. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput. Biomed. Res. 5:411-459.
60. Simon, N., E. Sampol, J. Albanese, C. Martin, P. Arvis, S. Urien, B. Lacarelle, and B. Bruguerolle. 2003. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Clin. Pharmacol. Ther. 74:353-363.
61. Srivastava, S., S. Musuka, C. Sherman, C. Meek, R. Leff, and T. Gumbo. Efflux pump derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and ethambutol pharmacokinetics-pharmacodynamics. J. Infect. Dis., in press.
62. Turnidge, J., and D. L. Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.
63. Wang, J. Y., J. T. Wang, T. H. Tsai, C. L. Hsu, C. J. Yu, P. R. Hsueh, L. N. Lee, and P. C. Yang. 2010. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 14:65-71.
64. Wilkins, J. J., G. Langdon, H. McIlleron, G. C. Pillai, P. J. Smith, and U. S. Simonsson. 2006. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur. J. Clin. Pharmacol. 62:727-735.
65. Wilkins, J. J., R. M. Savic, M. O. Karlsson, G. Langdon, H. McIlleron, G. Pillai, P. J. Smith, and U. S. Simonsson. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148.
66. Yamane, N., S. Ichiyama, S. Kawahara, Y. Iinuma, H. Saitoh, M. Shimojima, H. Udagawa, and I. Nakasone. 1999. Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis-evaluation of interlaboratory precision and interpretive compatibility with agar proportion method. Jpn. J. Clin. Pathol. 47:754-766.
67. Zhang, Y., S. Permar, and Z. Sun. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
68. Ziglam, H. M., D. R. Baldwin, I. Daniels, J. M. Andrew, and R. G. Finch. 2002. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50:1011-1015.